2022
Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection
Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch C, Justice A, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, Monforte A, Gill J, Ceron D, van Sighem A, Linas B, van der Valk M, Hernán M, Collaboration H. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection. Journal Of The International AIDS Society 2022, 25: e26048. PMID: 36562643, PMCID: PMC9784654, DOI: 10.1002/jia2.26048.Peer-Reviewed Original ResearchConceptsSustained virological responseHCV RNA testingDAA treatmentSVR ratesVirological responseProbability of SVRHepatitis C virus (HCV) cureRoutine HCV RNA testingActing antiviral (DAA) treatmentDAA treatment initiationCD4 cell countDirect antiviral agentsPresence of cirrhosisHCV RNA testEnd of treatmentClinical strataDAA recipientsHIV-HCVSVR assessmentSVR statusHIV acquisitionClinical characteristicsAntiviral treatmentTreatment initiationHCV genotypes
2020
Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
Do A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 2025-2034. PMID: 32342483, PMCID: PMC7352003, DOI: 10.1007/s11606-020-05782-6.Peer-Reviewed Original ResearchConceptsDAA treatmentExcess weight gainTreatment initiationWeight gainChronic hepatitis C virus (HCV) infectionHigh FIB-4 scoreHepatitis C virus infectionC virus infectionFIB-4 scoreHepatitis C infectionDirect acting antiviralsLiver disease progressionMultiple logistic regressionConclusionWeight gainDAA therapySVR achievementC infectionBaseline weightProspective studyExcess weightDisease progressionVirus infectionHigh riskPatientsBirth cohort
2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2016
Reply to: “Hepatitis C testing in U.S. veterans born 1945–1965: An update”
Justice AC, Esserman D, Sarkar S, Levin FL, Skanderson M, Lim JK. Reply to: “Hepatitis C testing in U.S. veterans born 1945–1965: An update”. Journal Of Hepatology 2016, 66: 239. PMID: 27717863, DOI: 10.1016/j.jhep.2016.09.019.Peer-Reviewed Original ResearchDisparities in hepatitis C testing in U.S. veterans born 1945–1965
Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945–1965. Journal Of Hepatology 2016, 65: 259-265. PMID: 27130843, PMCID: PMC4955712, DOI: 10.1016/j.jhep.2016.04.012.Peer-Reviewed Original ResearchMeSH KeywordsHepacivirusHepatitis CHepatitis C AntibodiesHumansMaleRisk FactorsUnited StatesVeteransConceptsUnited States Preventative Services Task ForceHCV testingHCV antibodiesRisk factorsHepatitis C virus testingHepatitis C virus infectionHealth systemVeterans Administration Health SystemBirth cohort testingHCV testing practicesHepatitis C testingNational screening policyPositive HCV RNAPredictors of testingC virus infectionVA health systemAdvanced liver fibrosisVeterans Administration dataCorporate Data WarehouseHCV positivityHCV RNAAdvanced fibrosisHCV testLiver fibrosisVirus infection
2014
Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings
Butt AA, Yan P, Shaikh OS, Freiberg MS, Re V, Justice AC, Sherman KE, Team T. Virologic response and haematologic toxicity of boceprevir‐ and telaprevir‐containing regimens in actual clinical settings. Journal Of Viral Hepatitis 2014, 22: 691-700. PMID: 25524834, PMCID: PMC5020421, DOI: 10.1111/jvh.12375.Peer-Reviewed Original ResearchConceptsSustained virologic responsePEG/RBVHaematologic toxicityActual clinical settingsSVR ratesVirologic responseClinical settingHaematologic adverse eventsHCV Infected VeteransInterferon/ribavirinHCV genotype 1HCV RNA valuesPivotal clinical trialsHepatitis C virusBaseline cirrhosisHIV coinfectionPrimary endpointTreatment-naïveAdverse eventsC virusClinical trialsGenotype 1Genotype 1aSevere toxicityBoceprevir
2013
Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals
Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, Klein M, Silverberg M, Gill M, Moore R, Gebo K, Sterling T, Butt A, for the NA-ACCORD of the IeDEA, Kirk G, Benson C, Bosch R, Collier A, Boswell S, Grasso C, Mayer K, Hogg R, Harrigan R, Montaner J, Cescon A, Brooks J, Buchacz K, Gebo K, Moore R, Carey J, Rodriguez B, Horberg M, Silverberg M, Horberg M, Thorne J, Goedert J, Jacobson L, Klein M, Rourke S, Burchell A, Rachlis A, Rico P, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Justice A, Dubrow R, Fiellin D, Sterling T, Haas D, Bebawy S, Turner M, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Webster E, Morton L, Simon B, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Hanna D, Rebeiro P, Wong C, Mendes A. Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. The Journal Of Infectious Diseases 2013, 208: 1240-1249. PMID: 23904290, PMCID: PMC3778973, DOI: 10.1093/infdis/jit373.Peer-Reviewed Original ResearchConceptsStage 3 CKDStage 5 CKDProgressive CKDAviremic subjectsHazard ratioGlomerular filtration rate decreaseChronic kidney disease riskHepatitis C virus replicationHCV seronegative subjectsHCV viremic subjectsAdjusted hazard ratioChronic kidney diseaseHepatitis C viremiaKidney disease riskConfidence intervalsC virus replicationAdvanced CKDAviremic individualsCKD incidenceHCV-viremicSeronegative subjectsC viremiaViremic subjectsKidney diseaseCKD
2003
Testing, Referral, and Treatment Patterns for Hepatitis C Virus Coinfection in a Cohort of Veterans with Human Immunodeficiency Virus Infection
Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barradas M, Team V. Testing, Referral, and Treatment Patterns for Hepatitis C Virus Coinfection in a Cohort of Veterans with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2003, 36: 1039-1046. PMID: 12684917, DOI: 10.1086/374049.Peer-Reviewed Original ResearchConceptsAlcohol consumptionHepatitis CHuman immunodeficiency virus-positive patientsHepatitis C virus coinfectionHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus-positive patientsC virus coinfectionUnderwent liver biopsyHepatitis C therapyImmunodeficiency virus infectionVirus-positive patientsHepatitis C treatmentTreatment of patientsCohort of veteransVeterans Affairs electronic medical recordsHepatitis C virusCurrent alcohol consumptionHealth care providersElectronic medical recordsC therapyCohort studyLiver biopsyTreatment patternsVirus coinfectionPsychiatric comorbidity